Last reviewed · How we verify
NCT05915884
The Triglyceride/Glucose Index and SGLT-2 Inhibitors
trial testing SGLT-2 inhibitors in Metabolic Disease in 55 participants. Completed in 28 January 2024.
28 October 2023
Quick facts
| Lead sponsor | Samsun Education and Research Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 55 |
| Start date | 10 June 2023 |
| Primary completion | 28 October 2023 |
| Estimated completion | 28 January 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- SGLT-2 inhibitors — full drug profile →
Conditions studied
- Metabolic Disease — all drugs for Metabolic Disease →
- Diabetes — all drugs for Diabetes →
Sponsor
Samsun Education and Research Hospital
Who can join
Adults 18 to 80, any sex, with Metabolic Disease or Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was designed to evaluate the change in triglyceride glucose index, one of the atherosclerotic markers, in patients with type 2 DM followed in the Internal Medicine Clinic of Samsun University, Samsun Training, and Research Hospital. Methods: The data of the patients who were followed up for at least 3 months by making a retrospective file review will be recorded and analyzed. It is planned to start the study following the ethics committee's approval.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05915884
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SGLT-2 inhibitors
Trials testing the same drug.
- NCT07105917 — SLGT2i for Neuroprotection in Patients With Acute Ischemic Stroke · Phase 3 · not yet recruiting
- NCT07482020 — SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose M · Phase 2 · recruiting
- NCT06491953 — SGLT2-inhibitors on PC-AKI · active not recruiting
- NCT02730377 — Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin Aft · Phase 4 · completed
Other recruiting trials for Metabolic Disease
Currently open trials in the same condition.
- NCT06575426 — A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes M · Phase 1, PHASE2 · recruiting
- NCT06938386 — Pilot Haskap Metabolite Timing Project · NA · active not recruiting
- NCT06954298 — Molecular Landscape of Complex Lifestyle Modification · NA · active not recruiting
- NCT06717581 — Variation in Drug Interactions in People With HIV (PLWH) Aged 60 Years and Older. · recruiting
- NCT06529965 — Evaluating a Digital Intervention for Alleviating Diabetes-specific Emotional Distress in Adults Living With T2DM · NA · recruiting
Other Samsun Education and Research Hospital trials
Trials by the same sponsor.
- NCT05979597 — The Effect of Adjuvant Dexamethasone on Postoperative Pain, Analgesic Consumption and Block Properties in SFIB · NA · completed
- NCT05450211 — Evaluation of Postoperative Analgesic Efficacy of Suprainguinal Fascia Iliaca Block · NA · completed
- NCT05344105 — Comparison of Postoperative Analgesic Efficacy of Transversalis Fascia Plan Block and Erector Spina Plan Block · NA · completed
- NCT05409586 — Risk Factors and the Role of Albumin-to-globulin Ratio in Idiopathic Granulomatous Mastitis · completed
- NCT05678920 — Validation of the Turkish Version of the Modified Early Obstetric Warning Systems (MEOWS) Charts · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05915884 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Samsun Education and Research Hospital
- Last refreshed: 26 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05915884.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing